STOP-PAIN: STandard Versus No Opioid Prescription After Prolapse and Anti-INcontinence Surgery Trial

Sponsor
The Cleveland Clinic (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04491617
Collaborator
(none)
139
1
2
28.1
4.9

Study Details

Study Description

Brief Summary

Overprescribing opioids is considered a major contributor to the opioid crisis. Hill et al. demonstrated that within a general surgery practice, over 70% of the prescribed opioid pills were never taken. Disturbingly, 45% of patients who did not take opioids at all on their day of discharge were discharged with an opioid prescription (Chen et al). Recent initiatives have attempted to utilize restrictive opioid prescribing protocols for postoperative pain management in which patients were prescribed a limited number of opioid tablets (Hallway et al) or prescribed opioids only if they were used as an inpatient (Mark et al). These well-conducted studies show that restrictive opioid prescribing policies achieve the goal of reducing excess opioid exposure without causing undue harm, inconvenience or dissatisfaction among patients.

The objective of this study is to determine if a restrictive opioid prescription protocol (in which patients are not prescribed postoperative opioids unless they request them) is acceptable to patients after ambulatory and major urogynecologic surgery, compared to standard opioid prescribing practices. The study investigators believe that physicians can capitalize on the new ability to electronically prescribe opioids for patients who require them, to prevent over-prescribing without impacting patient care. The study also intends to describe postoperative opioid use patterns in the urogynecologic population, including factors predictive of opioid use and non-use. The results of this research will have a significant and timely impact by helping to reduce opioid overprescribing and informing future prescribing guidelines in the field of urogynecology.

Condition or Disease Intervention/Treatment Phase
  • Other: Standard opioid prescribing
  • Other: Restrictive opioid prescribing
N/A

Detailed Description

Specific Aims

Aim 1. To compare patient satisfaction and pain control using two different opioid prescribing protocols.

The study investigators hypothesize that postoperative pain control and satisfaction will be non-inferior between patients not routinely prescribed opioids after surgery and those prescribed a standard quantity. Participants will be asked to rate their pain control during the first 7 postoperative days with validated questionnaires. Participants' satisfaction with pain control will be evaluated at their postoperative visit.

Aim 2. To examine opioid use patterns after ambulatory and major urogynecologic surgery.

The study investigators hypothesize that most postoperative patients will use few or no opioids after urogynecologic surgery, regardless of prescribing protocol. All participants will receive thorough counseling with detailed instructions on non-opioid pain management, as well as multimodal analgesia via ERAS protocol during the perioperative period. Participants will be asked to log their opioid and non-opioid medication use in the first postoperative week. The investigators will also assess the number of requests for opioid prescription (in those randomized to the restrictive protocol) and opioid refills (from patients in the standard protocol).

Aim 3. To determine patient and perioperative factors associated with opioid use after urogynecologic surgery.

The study investigators plan to collect and analyze demographic, clinical and psychometric data on all participants with the goal of predicting analgesic needs and opioid use after urogynecologic surgery. Results from this study will guide surgeons on how to tailor opioid prescriptions to the needs of each patient, based off individual patient and perioperative characteristics.

Study Design

Study Type:
Interventional
Actual Enrollment :
139 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
STandard Versus No Opioid Prescription After Prolapse and Anti-INcontinence Surgery: A Randomized Controlled, Non-inferiority Trial
Actual Study Start Date :
Aug 27, 2020
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Standard Opioid Protocol (Control)

Standard postoperative medications (opioids and non-opioids) are prescribed upon discharge after surgery

Other: Standard opioid prescribing
Patients are routinely prescribed opioid medications in addition to non-opioids.

Experimental: Restrictive Opioid Protocol (Intervention)

Only non-opioid analgesics (i.e. ibuprofen and acetaminophen) are prescribed upon discharge after surgery. Patients are allowed to request an opioid prescription if they so desire

Other: Restrictive opioid prescribing
Patients are prescribed non-opioid pain medications, and will be prescribed opioids only if they request them.

Outcome Measures

Primary Outcome Measures

  1. Patient satisfaction with pain control at 6 week postoperative visit [6-weeks]

    Patient satisfaction with postoperative pain control and how pain expectations were met will be assessed with a 5-point Likert scale at the postoperative visit ("Overall, how satisfied were you with your postoperative pain medication?" [ranked 1- Very Dissatisfied to 5- Very Satisfied] and "With regard to your expectations before surgery, did you have the amount of pain you expected, more pain, or less pain?" [ranked 1- Much less pain than I expected to 5- Much more pain than I expected]).

Secondary Outcome Measures

  1. Pain level scores during first postoperative week [1-week]

    Patients will be asked to report their pain level for the first 7 days postoperatively. Pain levels will be assessed using questions 1, 2 and 4 from the Modified Surgical Pain Scales (SPS), which measures pain at rest, during normal activities and quantifies unpleasantness of worst pain using an 11-point numeric rating score, with 0 representing 'No pain sensation' and 10 representing 'Most intense pain imaginable'. Higher scores indicate a greater amount of pain. REDCap or paper surveys will be used.

  2. Number of pain medication tablets used [1-week]

    Participants will be asked to log opioid and non-opioid medication in number of tablets used during the first postoperative week with either REDCap or paper surveys.

  3. Number of requests for new opioid prescription or refills [6-weeks]

    Investigators will track the number of requests for opioid prescriptions and opioid refills during the 6 week postoperative period.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age greater than 18 years old

  • Access to ancillary care, including phone advice, nurse and outpatient clinic numbers

  • Transportation to outpatient clinic or ability to access Virtual Care Visits

  • Able to speak and read English

  • Has decision-making capacity and able to provide consent for research participation

Exclusion Criteria:
  • History of substance abuse disorder

  • Chronic opioid use

  • Score greater than or equal to 30 on Pain Catastrophizing Scale

  • Allergy (not intolerance) to greater than or equal to 2 opioids

  • Contraindications to both NSAIDs and acetaminophen

  • Surgery scheduled on Friday or before major federal holiday

  • Patients undergoing concomitant colorectal procedures

  • Patients with perioperative complication (such as iatrogenic bowel and bladder injury, hemorrhage, unanticipated laparotomy or ICU admission)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cleveland Clinic Cleveland Ohio United States 44195

Sponsors and Collaborators

  • The Cleveland Clinic

Investigators

  • Principal Investigator: Cecile A Ferrando, M.D., M.P.H., The Cleveland Clinic

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
The Cleveland Clinic
ClinicalTrials.gov Identifier:
NCT04491617
Other Study ID Numbers:
  • 20-682
First Posted:
Jul 29, 2020
Last Update Posted:
Jul 12, 2022
Last Verified:
Jul 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by The Cleveland Clinic
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 12, 2022